Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial

Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial

Abstract Background Cardiogenic shock (CS) is associated with significant morbidity and mortality. The impact of beta-blocker (BB) use on patients who develop CS remains unknown. We sought to evaluate the clinical outcomes and hemodynamic response profiles in patients treated with BB in the 24 h pri...

Full description

Bibliographic Details
Main Authors: Pietro Di Santo, Rebecca Mathew, Richard G. Jung, Trevor Simard, Stephanie Skanes, Brennan Mao, F. Daniel Ramirez, Jeffrey A. Marbach, Omar Abdel-Razek, Pouya Motazedian, Simon Parlow, Kevin E. Boczar, Gianni D’Egidio, Steven Hawken, Jordan Bernick, George A. Wells, Alexander Dick, Derek Y. So, Christopher Glover, Juan J. Russo, Caroline McGuinty, Benjamin Hibbert, the CAPITAL DOREMI investigators
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Critical Care
Subjects:
Cardiogenic shock
Beta-blocker
Inotropes
Milrinone
Dobutamine
Online Access:https://doi.org/10.1186/s13054-021-03706-2

Internet

https://doi.org/10.1186/s13054-021-03706-2

Similar Items